Genmab and PDL BioPharma Close Sale of Antibody Manufacturin...(ance may differ materially from any futu...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Date:3/13/2008
ance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
Contact:
Helle Husted,
Sr. Director, Investor Relations,
T: +45-33-44-77-30,
M: +45-25-27-47-13,
Contact for PDL:
Kathleen Rinehart (Media)
+1-650-454-2543
Jean Suzuki (Investors)
+1-650-454-2648
Stock Exchange Release no. 09/2008
'/>"/>
| SOURCE Genmab A/S Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
3. Medarex Announces Completion of Sale of Shares in Genmab A/S
4. Genmabs Financial Calendar for 2008
5. Genmab Reaches Milestones in Ofatumumab Collaboration
6. Genmab Announces HuMax-CD32b Pre-Clinical Program
7. Roche Files IND for Second Genmab Antibody
8. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
9. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
10. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
11. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
Post Your Comments:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3
[0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference[0] China Biologic Products to Ring NASDAQ Opening Bell[0] Martek Signs Sole-Source Supply Agreement with Fonterra[0] Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
Other Biology Technology:BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 33SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
Breaking Biology News(10 mins):Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Pathological gambling may be successfully treated with medications for substance addiction 2UT Southwestern receives $700,000 from HHMI to promote medical education of Ph.D. students 2LA Eye Surgeon Performs 8 Corneal Transplants in Syria 48785 1LA Eye Surgeon Performs 8 Corneal Transplants in Syria 48785 2LA Eye Surgeon Performs 8 Corneal Transplants in Syria 48785 3AUDIO from Medialink and Amgen 3A Experts Agree Infection in Cancer Patients Impacts Treatment Success 48783 1Hydroxycut 28R 29 Litigation Focus of July 28 Conference in San Francisco 48781 1Hydroxycut 28R 29 Litigation Focus of July 28 Conference in San Francisco 48781 2Hydroxycut 28R 29 Litigation Focus of July 28 Conference in San Francisco 48781 3Hydroxycut 28R 29 Litigation Focus of July 28 Conference in San Francisco 48781 4
Other Biology News:US fires release large amounts of carbon dioxide 2US fires release large amounts of carbon dioxide 3MU researchers go nano, natural and green 2MU researchers go nano, natural and green 3MU researchers go nano, natural and green 4University of Pittsburgh cardiologists identify new cardiac arrest gene 2University of Pittsburgh cardiologists identify new cardiac arrest gene 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |